
  
    
      
        Background_NNP
        Rett_NNP syndrome_NN (_( OMIM_NNP #_# 312750_CD
        http_NN :_: /_NN /_NN www_NN ._. ncbi_NN ._. nlm_NN ._. nih_NN ._. gov_NN /_NN Omim_NNP /_NN )_) is_VBZ an_DT X-_NNP linked_VBD dominant_JJ
        disorder_NN that_WDT occurs_VBZ with_IN a_DT prevalance_NN of_IN 1_CD in_IN 10_CD ,_, 000_CD to_TO
        15_CD ,_, 000_CD births_NNS [_NN 1_CD ]_NN and_CC almost_RB exclusively_RB in_IN females_NNS ._.
        Named_VBN after_IN Andreas_NNP Rett_NNP who_WP first_RB recognized_VBD the_DT disorder_NN
        in_IN 1966_CD [_NN 2_CD ]_NN ,_, the_DT syndrome_NN is_VBZ characterized_VBN by_IN a_DT
        constellation_NN of_IN clinical_JJ findings_NNS that_WDT have_VBP resulted_VBN in_IN
        the_DT establishment_NN of_IN clinical_JJ criteria_NNS for_IN the_DT diagnosis_NN [_NN
        3_CD ]_NN ._. Common_NNP clinical_JJ features_NNS include_VBP early_JJ normal_JJ
        development_NN until_IN approximately_RB 6_CD -_: 18_CD months_NNS of_IN age_NN followed_VBN
        by_IN a_DT period_NN of_IN developmental_NN stagnation_NN and_CC subsequent_JJ
        regression_NN ,_, usually_RB by_IN 3_CD years_NNS of_IN life_NN ._. Characteristic_NNP
        findings_NNS include_VBP loss_NN of_IN speech_NN and_CC motor_NN skills_NNS ,_,
        deceleration_NN of_IN head_NN growth_NN ,_, stereotypic_JJ hand_NN movements_NNS ,_,
        seizures_NNS ,_, respiratory_JJ abnormalities_NNS ,_, scoliosis_NNS and_CC growth_NN
        delay_NN ._. Although_IN the_DT disorder_NN is_VBZ usually_RB sporadic_JJ ,_, due_JJ to_TO
        new_JJ mutations_NNS ,_, a_DT few_JJ familial_NN cases_NNS permitted_VBD exclusion_NN
        mapping_NN on_IN the_DT X_NNP chromosome_NN with_IN assignment_NN of_IN the_DT
        responsible_JJ gene_NN to_TO band_VB Xq_NNP 28_CD [_NN 4_CD 5_CD 6_CD ]_NN ._.
        Mutations_NNP in_IN MECP_NNP 2_CD ,_, the_DT gene_NN that_IN encodes_NNS the_DT DNA_NNP
        binding_JJ protein_NN MeCP_NNP 2_CD (_( methyl-_NN CpG_NNP binding_JJ protein_NN 2_LS )_) ,_, have_VBP
        been_VBN found_VBN in_IN approximately_RB 65_CD -_: 77_CD %_NN of_IN Rett_NNP syndrome_NN
        patients_NNS [_NN 7_CD 8_CD 9_CD 10_CD ]_NN ._. The_DT functional_JJ consequence_NN of_IN MECP_NNP 2_CD
        mutations_NNS resulting_VBG in_IN Rett_NNP syndrome_NN is_VBZ loss_NN of_IN function_NN ._.
        Three_CD of_IN the_DT four_CD MECP_NNP 2_CD exons_NNS encode_NN a_DT 486_CD amino_JJ acid_NN
        protein_NN that_WDT is_VBZ believed_VBN to_TO be_VB a_DT transcriptional_NN repressor_NN
        based_VBN on_IN in_IN vitro_NN studies_NNS ._. MeCP_NNP 2_CD 's_POS functional_JJ structure_NN
        consists_VBZ of_IN an_DT 84_CD amino_JJ acid_NN methyl-binding_JJ domain_NN (_( MBD_NNP )_) [_NN
        11_CD ]_NN and_CC a_DT 104_CD amino_JJ acid_NN transcriptional_NN repression_NN domain_NN
        (_( TRD_NNP )_) [_NN 12_CD ]_NN ._. The_DT MBD_NNP is_VBZ able_JJ to_TO bind_NN to_TO 5_CD -_: methyl_NN cytosine_NN
        residues_NNS of_IN a_DT single_JJ CpG_NNP dinucleotide_NN [_NN 11_CD ]_NN ._. Under_IN the_DT
        current_JJ model_NN ,_, MeCP_NNP 2_CD binds_NNS to_TO DNA_NNP ,_, then_RB complexes_NNS with_IN
        Sin_NNP 3_CD A_DT through_IN the_DT TRD_NNP and_CC recruits_VBZ histone_NN deacetylases_NNS
        (_( HDAC_NNP )_) ._. Deacetylation_NNP of_IN core_NN histones_NNS then_RB alters_NNS
        chromatin_NN structure_NN and_CC results_NNS in_IN transcriptional_NN
        repression_NN [_NN 13_CD 14_CD ]_NN ._.
        While_IN MeCP_NNP 2_CD is_VBZ a_DT ubiquitously_RB expressed_VBN protein_NN ,_, its_PRP$
        expression_NN is_VBZ highest_JJS in_IN the_DT brain_NN ,_, lung_NN and_CC spleen_NN and_CC
        less_RBR abundant_JJ in_IN the_DT kidney_NN and_CC heart_NN [_NN 15_CD 16_CD ]_NN ._. It_PRP 's_VBZ
        cellular_JJ localization_NN is_VBZ also_RB specific_JJ ,_, with_IN expression_NN in_IN
        neurons_NNS but_CC not_RB in_IN glia_NN ._. Expression_NNP levels_NNS in_IN brain_NN
        increase_NN postnatally_RB [_NN 16_CD ]_NN ._. These_DT findings_NNS explain_VBP why_WRB
        the_DT most_RBS prominent_JJ clinical_JJ features_NNS of_IN Rett_NNP syndrome_NN are_VBP
        related_VBN to_TO central_JJ nervous_JJ system_NN (_( CNS_NNP )_) dysfunction_NN ._. The_DT
        presence_NN of_IN growth_NN retardation_NN [_NN 17_CD ]_NN ,_, osteopenia_NN [_NN 18_CD ]_NN ,_,
        and_CC gastrointestinal_NN abnormalities_NNS ,_, however_RB ,_, suggest_VBP a_DT
        potentially_RB important_JJ role_NN for_IN MeCP_NNP 2_CD 's_POS function_NN in_IN the_DT
        peripheral_JJ and_CC autonomous_JJ nervous_JJ system_NN and_CC in_IN other_JJ
        tissues_NNS ._. Alternatively_RB ,_, while_IN MeCP_NNP 2_CD 's_POS expression_NN is_VBZ
        ubiquitous_JJ ,_, other_JJ methyl-_NN CpG_NNP binding_JJ proteins_NNS that_WDT exist_VBP
        within_IN complexes_NNS ,_, MBD_NNP 1_CD and_CC MBD_NNP 2_CD [_NN 19_CD ]_NN or_CC Kaiso_NNP [_NN 20_CD ]_NN ,_,
        may_MD reduce_VB the_DT effect_NN of_IN mutations_NNS in_IN MECP_NNP 2_CD in_IN peripheral_JJ
        organ_NN systems_NNS while_IN the_DT lack_NN of_IN such_JJ redundancy_NN may_MD lead_VB to_TO
        a_DT more_RBR pronounced_JJ phenotype_NN in_IN the_DT brain_NN ._. This_DT theory_NN
        remains_VBZ speculative_JJ ,_, however_RB ,_, since_IN the_DT tissue_NN specificity_NN
        and_CC definitive_JJ identification_NN of_IN functional_JJ redundancy_NN of_IN
        methyl-_NN CpG_NNP binding_JJ proteins_NNS have_VBP not_RB been_VBN established_VBN ._.
        Regardless_RB ,_, the_DT targets_NNS of_IN MeCP_NNP 2_CD modulation_NN remain_VB unknown_JJ
        in_IN the_DT brain_NN or_CC elsewhere_RB ._.
        To_TO identify_VB potential_JJ downstream_JJ targets_NNS of_IN MeCP_NNP 2_CD
        modulation_NN ,_, we_PRP have_VBP compared_VBN global_JJ gene_NN expression_NN
        patterns_NNS in_IN four_CD matched_VBN pairs_NNS of_IN clonally_RB derived_VBN mutant_JJ
        or_CC wild-type_JJ MECP_NNP 2_CD -_: expressing_VBG fibroblast_NN cell_NN strains_NNS from_IN
        girls_NNS with_IN Rett_NNP syndrome_NN ,_, and_CC in_IN five_CD wild-type_JJ and_CC four_CD
        mutant_JJ MeCP_NNP 2_CD -_: expressing_VBG lymphoblastoid_NN cell_NN lines_NNS ,_, by_IN
        hybridizing_VBG Affymetrix_NNP U_NNP 95_CD (_( A-E_NNP )_) oligonucleotide_NN
        microarrays_NNS ._. The_DT use_NN of_IN clonally_RB derived_VBN fibroblasts_NNS
        eliminated_VBD the_DT mosaic_JJ X_NNP inactivation_NN seen_VBN in_IN tissues_NNS from_IN
        most_JJS females_NNS with_IN Rett_NNP syndrome_NN ._. Furthermore_RB ,_, expression_NN
        patterns_NNS in_IN clones_NNS with_IN the_DT mutant_JJ MECP_NNP 2_CD allele_NN active_JJ were_VBD
        compared_VBN with_IN those_DT in_IN clones_NNS with_IN the_DT wild-type_JJ allele_NN on_IN
        the_DT active_JJ X_NNP chromosome_NN ._. Because_IN both_DT types_NNS of_IN clones_NNS are_VBP
        derived_VBN from_IN the_DT same_JJ individual_NN ,_, variability_NN introduced_VBN by_IN
        differences_NNS in_IN autosomal_NN genetic_JJ background_NN is_VBZ eliminated_VBN
        by_IN our_PRP$ experimental_JJ strategy_NN ._. The_DT use_NN of_IN lymphoblastoid_NN
        cell_NN lines_NNS ,_, while_IN not_RB all_DT clonally_RB derived_VBN ,_, expanded_VBD the_DT
        scope_NN of_IN genes_NNS to_TO be_VB assayed_JJ beyond_IN those_DT expressed_VBN in_IN skin_NN
        fibroblasts_NNS ._. Our_PRP$ interrogations_NNS identified_VBD a_DT statistically_RB
        significant_JJ number_NN of_IN genes_NNS with_IN differential_NN expression_NN
        patterns_NNS between_IN wild-type_JJ and_CC mutant_JJ cell_NN strains_NNS ,_,
        however_RB ,_, the_DT results_NNS across_IN multiple_JJ clones_NNS from_IN the_DT same_JJ
        individual_NN showed_VBD substantial_JJ variability_NN ,_, questioning_VBG the_DT
        significance_NN of_IN some_DT of_IN the_DT genes_NNS identified_VBN ._. The_DT
        lymphoblasts_NNS ,_, while_IN not_RB analysed_JJ in_IN a_DT matched_VBN comparison_NN ,_,
        yielded_VBD a_DT relatively_RB short_JJ list_NN of_IN genes_NNS with_IN differential_NN
        expression_NN that_WDT includes_VBZ some_DT potentially_RB interesting_JJ
        candidate_NN genes_NNS ._.
      
      
        Methods_NNP
        
          Cell_NNP culture_NN ,_, single_JJ cell_NN cloning_VBG and_CC nucleic_JJ acid_NN
          extraction_NN for_IN fibroblasts_NNS
          Four_CD fibroblast_NN strains_NNS from_IN females_NNS with_IN clinically_RB
          diagnosed_VBN Rett_NNP syndrome_NN were_VBD obtained_VBN from_IN Coriell_NNP Cell_NNP
          Repositories_NNP ._. MECP_NNP 2_CD mutations_NNS were_VBD identified_VBN in_IN our_PRP$
          laboratory_NN as_RB previously_RB reported_VBD [_NN 10_CD ]_NN [_NN GM_NNP 07982_CD :_:
          705_CD delG_NN ;_: GM_NNP 11270_CD :_: 916_CD C_NNP >_NN T_NN (_( R_NN 306_CD C_NNP )_) ;_: GM_NNP 11272_CD :_: 1155_CD del_FW 32_CD
          and_CC GM_NNP 11273_CD :_: 316_CD C_NNP >_NN T_NN (_( R_NN 106_CD W_NNP )_) ]_NN ._. From_IN each_DT of_IN the_DT four_CD
          cultures_NNS ,_, single-cell_JJ derived_VBN clonal_NN cell_NN strains_NNS were_VBD
          established_VBN ._. To_TO do_VB so_RB ,_, fibroblasts_NNS were_VBD trypsinized_JJ
          (_( 0_CD ._. 05_CD %_NN )_) (_( GibcoBRL_NNP Life_NNP Technologies_NNPS )_) and_CC diluted_VBN to_TO 100_CD
          cells_NNS /_NN ml_NN ._. By_IN using_VBG a_DT 125_CD μm_NN Stripper_NNP ™_NN Tip_NNP (_( MidAtlantic_NNP
          Diagnostics_NNPS ,_, Marlton_NNP ,_, NJ_NNP )_) under_IN direct_JJ microscopic_JJ
          visualization_NN ,_, individual_JJ cells_NNS were_VBD transferred_VBN to_TO 96_CD
          well_RB plates_NNS ._. Cells_NNP were_VBD grown_VBN with_IN filtered_VBN (_( 0_CD ._. 2_LS μm_NN )_)
          conditioned_VBN medium_NN that_WDT was_VBD prepared_VBN by_IN culturing_VBG the_DT
          primary_JJ cell_NN strain_NN for_IN two_CD days_NNS during_IN the_DT exponential_NN
          growth_NN phase_NN in_IN MEM-alpha_NNP (_( Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_, MO_NNP )_) with_IN 15_CD %_NN
          fetal_JJ calf_NN serum_NN (_( Gemini_NNP ,_, Woodland_NNP ,_, CA_NNP )_) ,_, penicillin_NN (_( 100_CD
          U_NNP /_NN ml_NN )_) ,_, streptomycin_NN (_( 100_CD μg_NN /_NN ml_NN )_) ,_, and_CC glutamine_NN (_( 290_CD
          ng_NN /_NN ml_NN )_) (_( GibcoBRL_NNP Life_NNP Technologies_NNPS )_) ._. Upon_IN confluency_NN of_IN
          the_DT well_NN ,_, the_DT cells_NNS were_VBD trypsinized_JJ and_CC expanded_VBN ._. Growth_NN
          rates_NNS and_CC cellular_JJ morphology_NN were_VBD closely_RB monitored_VBN ._.
          Only_RB clonal_NN cell_NN strains_NNS in_IN the_DT exponential_NN growth_NN phase_NN
          with_IN similar_JJ cell_NN and_CC clonal_NN morphology_NN were_VBD selected_VBN for_IN
          further_JJ study_NN ._. RNA_NNP was_VBD extracted_VBN using_VBG RNA_NNP STAT-_NNP 60_CD
          (_( Tel-_NNP Test_NNP Inc_NNP ._. ,_, Friendswood_NNP ,_, TX_NNP )_) from_IN eight_CD 150_CD mm_NN plates_NNS
          of_IN exponentially_RB growing_VBG sub-confluent_JJ cells_NNS that_WDT were_VBD at_IN
          similar_JJ passage_NN numbers_NNS ._. DNA_NNP was_VBD extracted_VBN from_IN two_CD
          additional_JJ 150_CD mm_NN plates_NNS using_VBG a_DT standard_JJ extraction_NN
          protocol_NN to_TO determine_VB X_NNP chromosome_NN inactivation_NN status_NN
          and_CC verify_VB monoclonality_NN ._.
        
        
          Cell_NNP culture_NN ,_, single_JJ cell_NN cloning_VBG and_CC nucleic_JJ acid_NN
          extraction_NN for_IN lymphoblasts_NNS
          Clonal_NNP cell_NN lines_NNS with_IN the_DT mutant_JJ MECP_NNP 2_CD allele_NN on_IN the_DT
          active_JJ X_NNP chromosome_NN were_VBD derived_VBN from_IN lymphoblastoid_NN cell_NN
          lines_NNS (_( LCLs_NNP )_) from_IN four_CD females_NNS with_IN clinically_RB diagnosed_VBN
          Rett_NNP syndrome_NN and_CC known_VBN mutations_NNS (_( T_NN 158_CD M_NNP ,_, 803_CD delG_NN ,_, R_NN 168_CD X_NNP )_)
          [_NN 10_CD ]_NN and_CC 1159_CD del_FW 28_CD (_( unpublished_JJ )_) using_VBG the_DT technique_NN
          described_VBD above_IN ._. Individual_JJ cells_NNS were_VBD cultured_JJ in_IN
          conditioned_VBN RPMI_NNP 1640_CD medium_NN with_IN 15_CD %_NN fetal_JJ calf_NN serum_NN ,_,
          penicillin_NN (_( 100_CD U_NNP /_NN ml_NN )_) ,_, streptomycin_NN (_( 100_CD U_NNP /_NN ml_NN )_) and_CC
          glutamine_NN (_( 290_CD ng_NN /_NN ml_NN )_) ._. Four_CD cell_NN lines_NNS from_IN females_NNS with_IN
          known_VBN MECP_NNP 2_CD mutations_NNS (_( R_NN 106_CD W_NNP ,_, R_NN 255_CD X_NNP ,_, and_CC two_CD with_IN
          803_CD delG_NN )_) but_CC completely_RB skewed_VBN X_NNP chromosome_NN inactivation_NN
          with_IN the_DT wild-type_JJ MECP_NNP 2_CD allele_NN on_IN the_DT active_JJ X_NNP
          chromosome_NN were_VBD also_RB cultured_JJ ._. In_IN addition_NN ,_, one_CD clonal_NN
          cell_NN line_NN with_IN the_DT wild-type_JJ MECP_NNP 2_CD allele_NN on_IN the_DT active_JJ X_NNP
          chromosome_NN was_VBD established_VBN using_VBG the_DT cloning_VBG technique_NN
          described_VBD above_IN ._. RNA_NNP was_VBD extracted_VBN using_VBG RNA_NNP STAT-_NNP 60_CD
          (_( Tel-_NNP Test_NNP Inc_NNP ._. ,_, Friendswood_NNP ,_, TX_NNP )_) ._. DNA_NNP was_VBD extracted_VBN using_VBG
          a_DT standard_JJ extraction_NN protocol_NN to_TO determine_VB X_NNP chromosome_NN
          inactivation_NN status_NN and_CC verify_VB monoclonality_NN ._.
        
        
          X_NN chromosome_NN inactivation_NN studies_NNS
          Clonality_NNP was_VBD further_RBR confirmed_VBD and_CC X_NNP chromosome_NN
          inactivation_NN status_NN was_VBD determined_VBN by_IN the_DT length_NN of_IN the_DT
          polymorphic_JJ CAG_NNP trinucleotide_NN repeat_NN on_IN the_DT inactive_JJ
          androgen_NN receptor_NN allele_NN [_NN 21_CD 22_CD ]_NN ._. Restriction_NNP
          digestion_NN of_IN four_CD restriction_NN sites_NNS between_IN the_DT flanking_VBG
          primers_NNS and_CC adjacent_JJ to_TO the_DT trinucleotide_NN repeat_NN were_VBD
          carried_VBN out_IN with_IN the_DT methylation_NN sensitive_JJ enzymes_NNS HpaII_NNP
          and_CC HhaI_NNP ._. Amplification_NNP of_IN the_DT undigested_JJ allele_NN that_WDT
          included_VBD the_DT trinucleotide_NN repeat_NN region_NN was_VBD performed_VBN
          using_VBG the_DT fluorescent-labeled_JJ primer_NN 5_CD '_POS -_: 6_CD FAM_NNP
          CTGTGAAGGTTGCTGTTCCTCAT-_NNP 3_CD '_POS and_CC the_DT unlabeled_JJ primer_NN
          5_CD '_POS -_: TCCAGAATCTGTTCCAGAGCGTGC-_NNP 3_CD '_'' ._. The_DT lengths_NNS of_IN the_DT
          amplification_NN products_NNS were_VBD identified_VBN using_VBG the_DT ABI_NNP 377_CD
          sequencer_NN with_IN the_DT GeneScan_NNP ™_NN fragment_NN analysis_NN software_NN
          (_( Applied_NNP Biosystems_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP )_) ._. Undigested_NNP DNA_NNP
          samples_NNS from_IN each_DT of_IN the_DT original_JJ cell_NN cultures_NNS were_VBD
          amplified_VBN to_TO determine_VB the_DT lengths_NNS of_IN each_DT allele_NN ._.
        
        
          Allele-specific_NNP MECP_NNP 2_CD transcript_NN analysis_NN
          Reverse_VBP transcription_NN of_IN 2_CD μg_NN of_IN total_JJ RNA_NNP was_VBD
          performed_VBN after_IN Dnase_NNP I_PRP digestion_NN (_( Roche_NNP Diagnostics_NNPS ,_,
          Indianapolis_NNP ,_, IN_IN )_) with_IN the_DT Superscript_NNP ™_NN II_NNP RNase_NNP
          H-R_NNP everse_NN Transcriptase_NNP (_( GibcoBRL_NNP Life_NNP Technologies_NNPS )_)
          protocol_NN for_IN cDNA_NN synthesis_NN using_VBG 500_CD ng_NN of_IN random_JJ
          hexamers_NNS ._. Absence_NNP of_IN DNA_NNP contamination_NN was_VBD verified_VBN by_IN
          amplification_NN of_IN the_DT intron_NN containing_VBG region_NN of_IN the_DT
          MECP_NNP 2_CD gene_NN between_IN exons_NNS 3_CD and_CC 4_CD using_VBG exon_NN 3_CD based_VBN
          primer_NN 5_CD '_POS -_: AGCCCGTGCAGCCATCAGCC-_NNP 3_CD '_POS and_CC exon_NN 4_CD based_VBN primer_NN
          5_CD '_POS -_: CTTCCCAGGACTTTTCTCCA-_NNP 3_CD '_'' ._. The_DT regions_NNS containing_VBG the_DT
          mutations_NNS were_VBD amplified_VBN by_IN PCR_NNP using_VBG primers_NNS and_CC
          conditions_NNS previously_RB described_VBD [_NN 7_CD ]_NN and_CC later_RB modified_VBN
          [_NN 23_CD ]_NN ._. PCR_NNP products_NNS were_VBD treated_VBN with_IN 1_CD U_NNP exonuclease_NN
          and_CC 1_CD U_NNP shrimp_NN alkaline_NN phosphatase_NN for_IN 15_CD min_NN at_IN 37_CD °_NN C_NNP ._.
          The_DT enzymes_NNS were_VBD heat_NN inactivated_JJ at_IN 75_CD °_NN C_NNP for_IN 15_CD minutes_NNS ._.
          Both_DT strands_NNS of_IN the_DT treated_VBN PCR_NNP product_NN were_VBD sequenced_JJ
          with_IN fluorescent_NN labelled_JJ terminator_NN nucleotides_NNS on_IN the_DT
          ABI_NNP PRISM_NNP ®_NN 377_CD DNA_NNP sequencer_NN ._. Cell_NNP clones_NNS expressing_VBG only_RB
          the_DT mutant_JJ MECP_NNP 2_CD allele_NN are_VBP called_VBN "_'' mutant_JJ clones_NNS "_'' ,_, and_CC
          cell_NN clones_NNS or_CC skewed_VBN cell_NN lines_NNS expressing_VBG only_RB the_DT
          normal_JJ MCP_NNP 2_CD allele_NN are_VBP called_VBN "_'' wild-type_JJ "_'' ._.
        
        
          Immunoblot_NNP analysis_NN with_IN MeCP_NNP 2_CD antibody_NN
          MeCP_NNP 2_CD protein_NN expression_NN in_IN fibroblast_NN clones_NNS and_CC
          lymphoblastoid_NN cell_NN lines_NNS was_VBD determined_VBN by_IN immunoblot_NN
          analysis_NN ._. Cells_NNP were_VBD washed_VBN twice_RB with_IN PBS_NNP and_CC lysed_JJ with_IN
          RIPA_NNP buffer_NN (_( 1_CD %_NN Triton_NNP X-_NNP 100_CD ,_, 1_CD %_NN NaDOC_NNP ,_, 0_CD ._. 1_CD %_NN SDS_NNP ,_, 158_CD mM_NN
          NaCl_NNP ,_, 10_CD mM_NN Tris_NNP pH_NN 7_CD ._. 2_CD ,_, 5_CD mM_NN NaEDTA_NNP and_CC 1_CD %_NN protease_NN
          inhibitors_NNS ,_, added_VBD just_RB before_IN use_NN )_) (_( Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_,
          MO_NNP )_) ._. The_DT homogenate_NN was_VBD sonicated_JJ ,_, followed_VBN by_IN
          centrifugation_NN at_IN 4_CD °_NN C_NNP for_IN 30_CD min_NN ._. The_DT supernatant_NN was_VBD
          saved_VBN for_IN immunoblot_NN ._. Equal_NNP quantities_NNS of_IN protein_NN ,_, as_IN
          determined_VBN by_IN a_DT protein_NN assay_NN (_( BioRad_NNP ,_, Hercules_NNP ,_, CA_NNP )_) ,_,
          were_VBD separated_VBN by_IN electrophoresis_NNS in_IN a_DT 12_CD %_NN
          SDS-polyacrylamide_NNP gel_NN ._. The_DT gel_NN was_VBD then_RB equilibrated_JJ in_IN
          transfer_NN buffer_NN for_IN 15_CD min_NN and_CC transferred_VBN to_TO a_DT
          polyvinylidine_NN difluoride_NN membrane_NN (_( Novex_NNP ,_, San_NNP Diego_NNP ,_,
          CA_NNP )_) ,_, also_RB equilibrated_JJ in_IN transfer_NN buffer_NN for_IN 15_CD min_NN ,_, for_IN
          1_CD hr_NN at_IN 100_CD V_NNP ._. The_DT membrane_NN was_VBD blocked_VBN overnight_JJ with_IN 5_CD %_NN
          non-fat_JJ milk_NN in_IN PBS_NNP at_IN 4_CD °_NN C_NNP ,_, and_CC incubated_JJ with_IN a_DT rabbit_NN
          polyclonal_NN antibody_NN (_( 1_CD :_: 2000_CD )_) against_IN a_DT peptide_NN
          (_( CPRPNREEPVDSRTP_NNP )_) at_IN the_DT C-_NNP terminal_NN region_NN of_IN MECP_NNP 2_CD
          (_( Upstate_NNP Biotechnology_NNP ,_, Lake_NNP Placid_NNP ,_, NY_NNP )_) at_IN room_NN
          temperature_NN for_IN 2_CD h_NN in_IN a_DT western_JJ wash_NN solution_NN (_( PBS_NNP
          containing_VBG 2_CD %_NN non-fat_JJ milk_NN ,_, 0_CD ._. 1_CD %_NN Tween_NNP 20_CD ,_, and_CC 350_CD mM_NN
          NaCl_NNP )_) ._. The_DT membrane_NN was_VBD washed_VBN in_IN the_DT same_JJ solution_NN and_CC
          then_RB incubated_JJ with_IN a_DT horseradish_NN peroxidase_NN conjugated_JJ
          secondary_JJ antibody_NN (_( 1_CD :_: 5000_CD )_) in_IN the_DT same_JJ solution_NN for_IN 30_CD
          min_NN ._. The_DT membrane_NN was_VBD subsequently_RB washed_VBN again_RB ,_, and_CC
          bound_VBN antibody_NN was_VBD detected_VBN with_IN an_DT ECL_NNP kit_NN (_( Amersham_NNP ,_,
          Piscataway_NNP ,_, NY_NNP )_) ._.
        
        
          Affymetrix_NNP oligonucleotide_NN array_NN (_( GeneChip_NNP ®_NN )_)
          hybridization_NN
          Messenger_NNP RNA_NNP was_VBD purified_JJ from_IN total_JJ RNA_NNP extract_VB
          using_VBG theOligotex_NN ™_NN batch_NN protocol_NN (_( Qiagen_NNP ,_, Valencia_NNP ,_, CA_NNP )_) ._.
          The_DT SuperScript_NNP ™_NN Choice_NNP System_NNP was_VBD used_VBN for_IN (_( ds_NNS )_) -_: cDNA_NN
          synthesis_NN (_( GibcoBRL_NNP Life_NNP Technologies_NNPS )_) using_VBG the_DT T_NN 7_CD -_: (_( dT_NN )_) 
          24_CD primer_NN
          5_CD '_POS -_: GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-_NNP (_( dT_NN )_) 
          24_CD -_: 3_CD '_POS and_CC 3_CD μg_NN of_IN mRNA_NN for_IN each_DT
          reaction_NN ._. Biotin-labeled_NNP in_IN vitro_NN transcription_NN (_( IVT_NNP )_) was_VBD
          accomplished_VBN with_IN the_DT Enzo_NNP BioArray_NNP ™_NN High_NNP Yield_NNP ™_NN
          transcript_NN labeling_VBG kit_NN (_( Affymetrix_NNP ,_, Santa_NNP Clara_NNP ,_, CA_NNP )_)
          using_VBG 4_CD μl_NN of_IN (_( ds_NNS )_) -_: cDNA_NN product_NN ._. IVT_NNP cleanup_NN was_VBD
          performed_VBN using_VBG Rneasy_NNP ®_NN Columns_NNP (_( Qiagen_NNP ,_, Valencia_NNP ,_, CA_NNP )_) ._.
          The_DT IVT_NNP product_NN was_VBD chemically_RB fragmented_VBN with_IN 40_CD mM_NN
          Tris-acetate_NNP ,_, pH_NN 8_CD ._. 1_CD ,_, 125_CD mM_NN KOAc_NNP and_CC 30_CD mM_NN MgOAc_NNP at_IN 94_CD °_NN C_NNP
          for_IN 35_CD minutes_NNS ._. The_DT fragmented_JJ product_NN was_VBD hybridized_JJ to_TO
          the_DT Affymetrix_NNP GeneChip_NNP ®_NN Human_NNP Genome_NNP U_NNP 95_CD Set_NNP (_( A-E_NNP )_)
          (_( Affymetrix_NNP ,_, Santa_NNP Clara_NNP ,_, CA_NNP )_) ._.
          Quality_JJ control_NN parameters_NNS were_VBD assessed_VBN throughout_IN
          the_DT experimental_JJ process_NN to_TO assure_VB the_DT quality_NN of_IN the_DT
          starting_VBG RNA_NNP ,_, the_DT efficiency_NN of_IN transcription_NN ,_, integrity_NN
          of_IN hybridization_NN ,_, and_CC consistency_NN of_IN qualitative_JJ calls_NNS ._.
          Assessment_NNP during_IN the_DT synthesis_NN of_IN the_DT hybridization_NN
          transcript_NN was_VBD accomplished_VBN by_IN spectrophotometric_JJ
          analysis_NN of_IN the_DT starting_VBG RNA_NNP and_CC cRNA_NN and_CC gel_NN
          electrophoresis_NNS following_VBG synthesis_NN of_IN the_DT cDNA_NN ,_, cRNA_NN and_CC
          fragmentation_NN of_IN the_DT cRNA_NN ._. A_DT 3_CD '_POS /_NN 5_CD '_POS ratio_NN of_IN GAPDH_NNP less_JJR
          than_IN 2_CD was_VBD considered_VBN acceptable_JJ for_IN efficiency_NN of_IN
          transcription_NN ._. Spiked_NNP control_NN transcripts_NNS were_VBD also_RB
          monitored_VBN to_TO verify_VB hybridization_NN integrity_NN ._. Scaling_NNP
          factors_NNS for_IN each_DT sample_NN ranged_VBD between_IN 0_CD ._. 88_CD and_CC 17_CD ._. 8_CD with_IN
          the_DT ratio_NN of_IN scaling_VBG factors_NNS between_IN samples_NNS for_IN a_DT given_VBN
          chip_NN ranging_VBG from_IN 1_CD ._. 4_CD to_TO 2_CD ._. 5_CD ._. All_DT quality_NN control_NN
          measures_NNS were_VBD consistent_JJ with_IN the_DT manufacturers_NNS
          recommended_VBD procedures_NNS and_CC conformed_JJ to_TO the_DT recommended_VBD
          cut-off_JJ values_NNS ._.
        
        
          Microarray_NNP data_NNS analysis_NN for_IN fibroblast_NN
          clones_NNS
          All_DT GeneChips_NNP ®_NN were_VBD analyzed_VBN using_VBG MicroArray_NNP Suite_NNP
          3_CD ._. 0_CD ™_NN (_( MAS_NNP 3_CD ._. 0_CD )_) with_IN target_NN intensities_NNS normalized_JJ to_TO
          2500_CD ._. Baseline_NNP genetic_JJ expression_NN profiles_NNS of_IN one_CD clonal_NN
          wild-type_JJ MeCP_NNP 2_CD -_: expressing_VBG fibroblast_NN strain_NN were_VBD
          compared_VBN to_TO the_DT expression_NN profile_NN of_IN the_DT matched_VBN clonal_NN
          mutant_JJ MeCP_NNP 2_CD -_: expressing_VBG cell_NN strain_NN ,_, for_IN each_DT of_IN four_CD
          different_JJ MECP_NNP 2_CD mutations_NNS ._. Analyzed_NNP data_NNS were_VBD imported_VBN to_TO
          MicroDB_NNP ™_NN and_CC queried_VBN using_VBG Affymetrix_NNP 's_POS Data_NNP Mining_NNP Tool_NNP
          (_( DMT_NNP )_) ._. All_DT four_CD matched_VBN pair_NN comparisons_NNS were_VBD queried_VBN for_IN
          directional_NN changes_NNS ._. For_IN genes_NNS /_NN ESTs_NNP with_IN increased_VBN levels_NNS
          of_IN expression_NN ,_, defined_VBN by_IN MAS_NNP 3_CD ._. 0_CD as_RB marginally_RB increased_VBN
          or_CC increased_VBN ,_, wild-type_JJ baseline_NN expression_NN levels_NNS could_MD
          be_VB present_JJ or_CC absent_JJ ._. For_IN genes_NNS with_IN decreased_VBD levels_NNS of_IN
          expression_NN ,_, defined_VBN by_IN MAS_NNP 3_CD ._. 0_CD as_RB marginally_RB decreased_VBD or_CC
          decreased_VBD ,_, wild-type_JJ baseline_NN expression_NN levels_NNS were_VBD
          required_VBN to_TO be_VB present_JJ ._. We_PRP identified_VBD genes_NNS that_WDT
          demonstrated_VBD the_DT same_JJ directional_NN change_NN in_IN at_IN least_JJS
          three_CD of_IN four_CD comparisons_NNS ._. We_PRP computed_JJ p_NN values_NNS for_IN genes_NNS
          identified_VBN by_IN this_DT criterion_NN ._. We_PRP assumed_VBD that_IN if_IN a_DT gene_NN
          was_VBD not_RB subject_JJ to_TO a_DT systematic_JJ change_NN in_IN expression_NN
          level_NN ,_, an_DT observed_VBN directional_NN change_NN in_IN a_DT given_VBN mutant_JJ
          strain_NN would_MD occur_VB randomly_RB and_CC independently_RB with_IN
          probability_NN equal_JJ to_TO the_DT overall_JJ proportion_NN of_IN
          directional_NN changes_NNS observed_VBD in_IN that_DT mutant_JJ strain_NN ._. We_PRP
          used_VBD one-sample_JJ ,_, two-sided_JJ t-tests_JJ on_IN the_DT reported_VBN
          GeneChip_NNP ®_NN fold_VB changes_NNS to_TO assess_VB whether_IN the_DT log_NN fold_VB
          changes_NNS of_IN mutant_JJ cell_NN strains_NNS differ_VBP from_IN zero_CD on_IN
          average_NN ._. We_PRP report_VBP the_DT corresponding_JJ 95_CD %_NN confidence_NN
          intervals_NNS (_( CI_NNP )_) after_IN conversion_NN back_RB from_IN the_DT log_NN scale_NN ._.
          Although_IN the_DT assumptions_NNS of_IN the_DT t-test_JJ cannot_NN be_VB
          verified_VBN ,_, there_EX was_VBD insufficient_JJ data_NNS to_TO carry_VB out_IN
          alternative_JJ tests_NNS ._.
        
        
          Microarray_NNP data_NNS analysis_NN for_IN lymphoblastoid_NN cell_NN
          lines_NNS
          All_DT GeneChips_NNP ®_NN were_VBD analyzed_VBN using_VBG MAS_NNP 3_CD ._. 0_CD with_IN target_NN
          intensities_NNS normalized_JJ to_TO 2500_CD ._. Only_RB one_CD lymphoblast_NN cell_NN
          line_NN yielded_VBD both_DT a_DT clonal_NN wild-type_JJ and_CC clonal_NN mutant_JJ
          cell_NN line_NN (_( 1159_CD del_FW 28_CD )_) ._. Baseline_NNP expression_NN profiles_NNS were_VBD
          derived_VBN from_IN the_DT clonal_NN wild-type_JJ cell_NN line_NN (_( 1159_CD del_FW 28_CD )_) ,_,
          and_CC the_DT four_CD completely_RB skewed_VBN wild-type_JJ cell_NN line_NN
          controls_NNS (_( R_NN 106_CD W_NNP ,_, R_NN 255_CD X_NNP ,_, 803_CD delG_NN ,_, 803_CD delG_NN )_) ._. Expression_NNP
          profiles_NNS from_IN the_DT mutant_JJ clonal_NN cell_NN line_NN (_( 1159_CD del_FW 28_CD )_) and_CC
          three_CD additional_JJ clonal_NN mutant_JJ MeCP_NNP 2_CD expressing_VBG cell_NN
          lines_NNS (_( T_NN 158_CD M_NNP ,_, 803_CD delG_NN ,_, R_NN 168_CD X_NNP )_) were_VBD compared_VBN to_TO the_DT
          baseline_NN expression_NN profiles_NNS ._. Each_DT mutant_JJ expression_NN
          profile_NN was_VBD compared_VBN to_TO each_DT wild-type_JJ control_NN profile_NN
          yielding_VBG 20_CD comparisons_NNS ._. Analyzed_NNP data_NNS was_VBD imported_VBN to_TO
          MicroDB_NNP ™_NN and_CC queried_VBN using_VBG DMT_NNP ._. All_DT 20_CD comparisons_NNS were_VBD
          queried_VBN to_TO identify_VB genes_NNS that_WDT demonstrated_VBD similar_JJ
          directional_NN changes_NNS in_IN at_IN least_JJS 15_CD of_IN 20_CD unmatched_JJ pair_NN
          comparisons_NNS (_( four_CD mutant_JJ samples_NNS compared_VBN individually_RB to_TO
          each_DT of_IN five_CD wild-type_JJ samples_NNS )_) ._. For_IN genes_NNS with_IN increased_VBN
          levels_NNS of_IN expression_NN ,_, defined_VBN by_IN MAS_NNP 3_CD ._. 0_CD as_RB marginally_RB
          increased_VBN or_CC increased_VBN ,_, wild-type_JJ baseline_NN expression_NN
          levels_NNS could_MD be_VB present_JJ or_CC absent_JJ ._. For_IN genes_NNS with_IN
          decreased_VBD levels_NNS of_IN expression_NN ,_, defined_VBN by_IN MAS_NNP 3_CD ._. 0_CD as_RB
          marginally_RB decreased_VBD or_CC decreased_VBD ,_, wild-type_JJ baseline_NN
          expression_NN levels_NNS were_VBD required_VBN to_TO be_VB present_JJ ._. We_PRP used_VBD
          two-sided_JJ Wilcoxon_NNP rank-sum_JJ tests_NNS on_IN the_DT reported_VBN
          uncompared_JJ values_NNS for_IN the_DT two_CD groups_NNS to_TO test_VB whether_IN the_DT
          expression_NN profiles_NNS of_IN mutant_JJ cell_NN lines_NNS differ_VBP from_IN
          those_DT of_IN wild-type_JJ cell_NN lines_NNS ._.
        
        
          Real-time_NNP comparative_JJ quantitative_JJ PCR_NNP
          Total_NNP RNA_NNP from_IN the_DT four_CD matched_VBN pairs_NNS of_IN clonal_NN
          fibroblast_NN cell_NN strains_NNS and_CC ten_CD lymphoblast_NN cell_NN lines_NNS
          used_VBN on_IN the_DT GeneChips_NNP ®_NN was_VBD used_VBN as_IN template_NN for_IN RT-PCR_NNP to_TO
          independently_RB assess_VB the_DT validity_NN of_IN Affymetrix_NNP GeneChip_NNP
          ®_NN data_NNS ._. Each_DT RT_NNP reaction_NN was_VBD performed_VBN with_IN RNA_NNP from_IN the_DT
          same_JJ preparation_NN used_VBN for_IN the_DT GeneChip_NNP ®_NN hybridization_NN ._.
          Total_NNP RNA_NNP from_IN eight_CD additional_JJ clonal_NN cell_NN strains_NNS (_( four_CD
          mutant_JJ and_CC four_CD wild-type_JJ )_) with_IN the_DT R_NN 106_CD W_NNP mutation_NN and_CC
          fourteen_CD additional_JJ clonal_NN cell_NN strains_NNS (_( seven_CD mutant_JJ and_CC
          seven_CD wild-type_JJ )_) with_IN the_DT 1155_CD del_FW 32_CD mutation_NN were_VBD also_RB
          used_VBN as_IN template_NN for_IN RT-PCR_NNP to_TO assess_VB consistency_NN of_IN
          results_NNS across_IN different_JJ clonal_NN fibroblast_NN cell_NN strains_NNS ._.
          Reverse_VBP transcription_NN of_IN total_JJ RNA_NNP was_VBD performed_VBN after_IN
          Dnase_NNP I_PRP digestion_NN (_( Roche_NNP Diagnostics_NNPS ,_, Indianapolis_NNP ,_, IN_IN )_)
          with_IN the_DT Superscript_NNP ™_NN II_NNP Rnase_NNP H_NNP -_: Reverse_VBP Transcriptase_NNP
          (_( GibcoBRL_NNP Life_NNP Technologies_NNPS )_) protocol_NN for_IN cDNA_NN synthesis_NN
          using_VBG 2_CD μg_NN of_IN total_JJ RNA_NNP and_CC 1_CD μg_NN of_IN random_JJ hexamers_NNS ._.
          Absence_NNP of_IN DNA_NNP contamination_NN was_VBD verified_VBN by_IN amplifying_VBG
          the_DT 756_CD bp_NN intron_NN containing_VBG region_NN of_IN the_DT MECP_NNP 2_CD gene_NN
          between_IN exons_NNS 3_CD and_CC 4_CD using_VBG exon_NN 3_CD based_VBN primer_NN
          5_CD '_POS -_: AGCCCGTGCAGCCATCAGCC-_NNP 3_CD '_POS and_CC exon_NN 4_CD based_VBN primer_NN
          5_CD '_POS -_: CTTCCCAGGACTTTTCTCCA-_NNP 3_CD '_'' ._. Minus_NNP RT_NNP samples_NNS tested_VBN
          simultaneously_RB with_IN experimental_JJ samples_NNS by_IN quantitative_JJ
          RT-PCR_NNP with_IN Sybr_NNP ®_NN Green_NNP consistently_RB yielded_VBD no_DT
          amplification_NN below_IN 33_CD cycles_NNS using_VBG the_DT above_JJ protocol_NN ._.
          The_DT RT_NNP product_NN was_VBD diluted_VBN 10_CD fold_VB ,_, aliquoted_JJ and_CC stored_VBD
          at_IN -_: 80_CD °_NN C_NNP ._. Forward_NNP and_CC reverse_VB primers_NNS were_VBD designed_VBN using_VBG
          Applied_NNP Biosystem_NNP 's_POS Primer_NNP Express_NNP v_NN 1_CD ._. 0_CD ™_NN software_NN
          (_( Applied_NNP Biosystems_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP )_) from_IN consensus_NN
          sequences_NNS provided_VBN by_IN Affymetrix_NNP
          http_NN :_: /_NN /_NN www_NN ._. netaffx_NN ._. comfor_NN each_DT gene_NN of_IN interest_NN ._. Each_DT 25_CD
          μl_NN PCR_NNP mix_NN contained_VBD 7_CD ._. 875_CD μl_NN Sybr_NNP ®_NN Green_NNP Master_NNP Mix_NNP (_( 1_CD X_NNP
          Sybr_NNP ®_NN Green_NNP Buffer_NNP ,_, 3_CD mM_NN MgCl_NNP 
          2_CD ,_, 200_CD nM_NN dNTP_NN blend_NN ,_, 0_CD ._. 6275_CD U_NNP
          Amplitaq_NNP Gold_NNP ®_NN ,_, 0_CD ._. 25_CD U_NNP AmpErase_NNP ®_NN UNG_NNP )_) ,_, 200_CD -_: 400_CD nM_NN
          forward_RB and_CC reverse_VB primers_NNS and_CC approximately_RB 5_CD ng_NN
          template_NN ._. Cycle_NNP conditions_NNS for_IN the_DT ABI_NNP 7700_CD were_VBD 50_CD °_NN C_NNP for_IN
          2_CD minutes_NNS ,_, 95_CD °_NN C_NNP for_IN 10_CD minutes_NNS and_CC 35_CD cycles_NNS of_IN 95_CD °_NN C_NNP for_IN
          15_CD sec_NN and_CC 60_CD °_NN C_NNP for_IN 1_CD minute_NN ._. The_DT average_NN of_IN four_CD
          endogenous_JJ controls_NNS (_( GAPDH_NNP ,_, β_NN actin_NN ,_, TATA_NNP IID_NNP and_CC
          transferrin_NN )_) was_VBD used_VBN to_TO normalize_VB the_DT amount_NN of_IN template_NN
          for_IN each_DT wild-type_JJ and_CC mutant_JJ pair_NN ._. Each_DT reaction_NN was_VBD run_VBN
          in_IN triplicate_NN with_IN the_DT results_NNS averaged_VBD on_IN the_DT log_NN (_( base_NN
          2_LS )_) scale_NN ._. Standard_JJ curves_NNS for_IN each_DT amplification_NN product_NN
          were_VBD generated_VBN from_IN 10_CD -_: fold_VB dilutions_NNS of_IN pooled_VBN cDNA_NN to_TO
          determine_VB primer_NN efficiency_NN ._. Data_NNP was_VBD analyzed_VBN with_IN
          Microsoft_NNP Excel_NNP 2000_CD to_TO generate_VB raw_JJ expression_NN
          values_NNS ._.
          We_PRP performed_VBD paired_VBN t-tests_JJ on_IN the_DT RT-PCR_NNP values_NNS for_IN
          the_DT original_JJ set_NN of_IN fibroblast_NN clones_NNS to_TO test_VB whether_IN the_DT
          average_JJ log_NN change_NN across_IN cell_NN strains_NNS differs_VBZ from_IN zero_CD ._.
          We_PRP used_VBD unpaired_JJ t_NN tests_NNS for_IN the_DT second_RB set_NN of_IN fibroblast_NN
          clones_NNS from_IN each_DT of_IN two_CD cell_NN strains_NNS to_TO determine_VB whether_IN
          multiple_JJ clones_NNS from_IN individuals_NNS undergo_VBP a_DT systematic_JJ
          fold_VB change_NN ._. We_PRP used_VBD unpaired_JJ Wilcoxon_NNP rank-sum_JJ tests_NNS for_IN
          the_DT lymphoblast_NN cell_NN lines_NNS to_TO test_VB whether_IN there_EX is_VBZ a_DT
          systematic_JJ fold_VB change_NN across_IN lines_NNS ._. All_DT reported_VBD 95_CD %_NN
          confidence_NN intervals_NNS are_VBP reported_VBN in_IN terms_NNS of_IN fold_VB
          changes_NNS ,_, but_CC derived_VBD from_IN t-tests_JJ computed_JJ on_IN the_DT log_NN
          scale_NN ._.
        
      
      
        Results_NNS
        
          Characterization_NNP of_IN clonal_NN cell_NN strains_NNS
          Clonal_NNP mutant_JJ and_CC wild-type_JJ MECP_NNP 2_CD expressing_VBG
          fibroblast_NN cell_NN strains_NNS were_VBD successfully_RB established_VBN
          from_IN four_CD Rett_NNP females_NNS with_IN different_JJ mutations_NNS ,_, one_CD
          missense_NN in_IN the_DT MBD_NNP ,_, one_CD missense_NN in_IN the_DT TRD_NNP and_CC two_CD
          frameshift_NN mutations_NNS leading_VBG to_TO premature_JJ stop_NN codons_NNS ._.
          Clonality_NNP was_VBD established_VBN by_IN three_CD independent_JJ methods_NNS :_:
          visualization_NN of_IN each_DT cell_NN transferred_VBN for_IN clonal_NN
          culture_NN ,_, X_NNP inactivation_NN pattern_NN analysis_NN of_IN the_DT
          polymorphic_JJ androgen_NN receptor_NN alleles_NNS using_VBG GeneScan_NNP ™_NN ,_,
          and_CC identification_NN of_IN single-allele_JJ MECP_NNP 2_CD transcripts_NNS
          (_( Fig_NNP ._. 1_LS )_) ._.
          The_DT levels_NNS of_IN MECP_NNP 2_CD transcripts_NNS were_VBD virtually_RB
          identical_JJ by_IN real-time_JJ quantitative_JJ RT-PCR_NNP analysis_NN (_( less_JJR
          than_IN 0_CD ._. 27_CD cycle_NN thresholds_NNS difference_NN )_) across_IN all_DT eight_CD
          clones_NNS ,_, one_CD wild-type_JJ and_CC one_CD mutant_JJ from_IN each_DT
          individual_NN ,_, that_WDT were_VBD used_VBN for_IN oligonucleotide_NN array_NN
          hybridization_NN (_( data_NNS not_RB shown_VBN )_) ._. This_DT result_NN is_VBZ not_RB
          surprising_JJ ._. Given_VBN the_DT fact_NN that_IN the_DT premature_JJ termination_NN
          codons_NNS resulting_VBG from_IN the_DT frameshift_NN mutations_NNS are_VBP all_DT
          located_VBN in_IN the_DT 3_CD '_POS final_JJ exon_NN of_IN the_DT MECP_NNP 2_CD gene_NN ,_,
          preferential_JJ degradation_NN of_IN nonsense_NN codon-containing_JJ
          transcripts_NNS would_MD not_RB be_VB expected_VBN [_NN 24_CD ]_NN ._.
          To_TO assess_VB MeCP_NNP 2_CD expression_NN at_IN the_DT protein_NN level_NN ,_,
          immunoblot_NN analysis_NN with_IN an_DT antibody_NN against_IN the_DT
          C-_NNP terminal_NN region_NN of_IN MeCP_NNP 2_CD was_VBD carried_VBN out_IN on_IN total_JJ cell_NN
          lysates_NNS from_IN all_DT eight_CD fibroblast_NN clones_NNS ,_, and_CC from_IN some_DT
          of_IN the_DT LCLs_NNP ,_, that_WDT were_VBD used_VBN for_IN array_NN hybridization_NN (_( Fig_NNP ._.
          2_LS )_) ._. A_DT reacting_VBG protein_NN band_NN (_( at_IN the_DT molecular_JJ weight_NN of_IN
          75_CD kD_NN ,_, as_IN indicated_VBN by_IN the_DT company_NN ,_,
          http_NN :_: /_NN /_NN www_NN ._. upstate_JJ ._. com_NN )_) was_VBD seen_VBN in_IN wild-type_JJ cell_NN lines_NNS
          expressing_VBG a_DT normal_RB sized_VBD MeCP_NNP 2_CD protein_NN ,_, and_CC in_IN cell_NN
          lines_NNS with_IN missense_NN mutations_NNS (_( FB_NNP R_NNP 106_CD W_NNP ,_, FB_NNP R_NNP 306_CD C_NNP and_CC LCL_NNP
          T_NN 158_CD M_NNP )_) ._. Cell_NNP clones_NNS expressing_VBG an_DT allele_NN with_IN a_DT
          truncating_VBG mutation_NN (_( FB_NNP 705_CD delG_NN ,_, FB_NNP 1155_CD del_FW 32_CD ,_, LCL_NNP
          R_NNP 168_CD X_NNP )_) ,_, do_VBP not_RB produce_VB a_DT normal_RB sized_VBD MECP_NNP 2_CD protein_NN ._. Due_JJ
          to_TO the_DT location_NN of_IN the_DT epitope_NN ,_, the_DT antibody_NN would_MD not_RB
          react_VB with_IN putative_JJ truncated_JJ proteins_NNS ._. The_DT bands_NNS seen_VBN at_IN
          approximately_RB 48_CD and_CC 100_CD kD_NN are_VBP unidentified_JJ proteins_NNS
          that_IN cross-react_JJ with_IN the_DT MeCP_NNP 2_CD antibody_NN ._. The_DT absence_NN of_IN
          a_DT normal_RB sized_VBD MeCP_NNP 2_CD protein_NN in_IN mutant_JJ clones_NNS with_IN
          truncating_VBG mutations_NNS confirms_VBZ their_PRP$ purity_NN ,_, and_CC ,_, together_RB
          with_IN the_DT presence_NN of_IN MeCP_NNP 2_CD in_IN the_DT wild-type_JJ clones_NNS ,_,
          validates_NNS these_DT matched_VBN pairs_NNS of_IN cell_NN cultures_NNS as_IN a_DT
          useful_JJ experimental_JJ system_NN for_IN the_DT search_NN of_IN downstream_JJ
          effects_NNS of_IN MeCP_NNP 2_CD deficiency_NN ._.
        
        
          Oligonucleotide_NNP array_NN hybridization_NN data_NNS of_IN matched_VBN
          fibroblast_NN clones_NNS
          The_DT percent_NN "_'' present_JJ "_'' calls_VBZ ranged_VBN from_IN 13_CD %_NN (_( chip_NN D_NNP )_)
          to_TO 55_CD %_NN (_( chip_NN A_DT )_) ._. Standard_JJ deviations_NNS for_IN the_DT percent_NN
          "_'' present_JJ "_'' calls_VBZ for_IN a_DT given_VBN chip_NN were_VBD 1_CD -_: 3_CD %_NN ._. There_EX were_VBD no_DT
          significant_JJ differences_NNS in_IN percent_NN "_'' present_JJ "_'' calls_VBZ
          between_IN MeCP_NNP 2_CD -_: deficient_NN and_CC MeCP_NNP 2_CD -_: positive_JJ samples_NNS ._. A_DT
          total_NN of_IN 252_CD ,_, 700_CD comparisons_NNS (_( four_CD Rett_NNP females_NNS ×_NN 63_CD ,_, 175_CD
          interrogations_NNS on_IN five_CD GeneChips_NNP ®_NN )_) revealed_VBD 6_CD ,_, 745_CD
          increased_VBN (_( or_CC marginally_RB increased_VBN )_) genes_NNS /_NN ESTs_NNP and_CC 6_CD ,_, 966_CD
          decreased_VBD (_( or_CC marginally_RB decreased_VBD )_) genes_NNS /_NN ESTs_NNP ._. The_DT
          number_NN of_IN genes_NNS with_IN increased_VBN (_( +_NN )_) and_CC decreased_VBD (_( -_: )_)
          levels_NNS of_IN expression_NN in_IN mutant_JJ MeCP_NNP 2_CD over_IN wild-type_JJ
          expressing_VBG clones_NNS differed_VBD among_IN the_DT fibroblast_NN strains_NNS
          studied_VBN (_( R_NN 106_CD W_NNP :_: 889_CD +_NN ,_, 3056_CD -_: ;_: R_NN 306_CD C_NNP :_: 1700_CD +_NN ,_, 1435_CD -_: ;_:
          705_CD delG_NN :_: 1160_CD +_NN ,_, 1240_CD -_: ;_: 1155_CD del_FW 32_CD :_: 2996_CD +_NN ,_, 1235_CD -_: )_) ._. The_DT
          unadjusted_JJ p_NN value_NN for_IN any_DT one_CD gene_NN that_WDT was_VBD increased_VBN
          (_( decreased_VBD )_) in_IN three_CD out_IN of_IN four_CD matched_VBN pair_NN comparisons_NNS
          was_VBD ._. 000060_CD (_( ._. 000075_CD )_) ._. The_DT p_NN value_NN for_IN any_DT gene_NN that_WDT
          increased_VBD (_( decreased_VBD )_) in_IN all_DT four_CD comparisons_NNS was_VBD 3_CD ._. 29_CD E_NNP
          -_: 07_CD (_( 4_CD ._. 72_CD E_NNP -_: 07_CD )_) ._.
          Forty-six_NNP genes_NNS showed_VBD increased_VBN levels_NNS of_IN expression_NN
          in_IN mutant_JJ cells_NNS in_IN three_CD out_IN of_IN four_CD comparisons_NNS ._. Three_CD
          genes_NNS were_VBD increased_VBN in_IN all_DT four_CD comparisons_NNS ._. Of_IN the_DT 49_CD
          genes_NNS ,_, 29_CD had_VBD been_VBN annotated_JJ as_IN known_VBN genes_NNS and_CC 20_CD as_IN
          unknown_JJ transcripts_NNS ._. Of_IN those_DT ,_, 7_CD were_VBD found_VBN to_TO encode_NN
          known_VBN genes_NNS by_IN searching_VBG recent_JJ database_NN releases_NNS and_CC the_DT
          Celera_NNP database_NN (_( Table_NNP 1_LS )_) ._. Expression_NNP levels_NNS of_IN two_CD genes_NNS
          (_( VSHK_NNP 1_CD and_CC CA_NNP 12_CD )_) ,_, represented_VBD twice_RB on_IN the_DT chips_NNS with_IN
          different_JJ accession_NN numbers_NNS ,_, were_VBD increased_VBN in_IN both_DT
          cases_NNS ._. Of_IN the_DT 47_CD unique_JJ genes_NNS with_IN increased_VBN transcript_NN
          levels_NNS in_IN MeCP_NNP 2_CD deficient_NN cells_NNS ,_, 32_CD are_VBP known_VBN to_TO be_VB
          expressed_VBN in_IN brain_NN (_( Table_NNP 1_LS )_) ._.
          Twenty-one_CD genes_NNS demonstrated_VBN decreased_VBD levels_NNS of_IN
          expression_NN in_IN three_CD out_IN of_IN four_CD matched_VBN comparisons_NNS ._. Of_IN
          the_DT 21_CD genes_NNS ,_, 13_CD had_VBD been_VBN annotated_JJ as_IN known_VBN genes_NNS and_CC 8_CD
          as_IN unknown_JJ transcripts_NNS ,_, of_IN which_WDT one_CD was_VBD found_VBN to_TO encode_NN
          a_DT known_VBN gene_NN by_IN searching_VBG recent_JJ database_NN releases_NNS and_CC
          the_DT Celera_NNP database_NN (_( Table_NNP 2_LS )_) ._. Oligonucleotide_NNP probes_NNS for_IN
          two_CD of_IN the_DT genes_NNS (_( COMP_NNP and_CC IGFBP_NNP 5_LS )_) were_VBD represented_VBN twice_RB
          on_IN the_DT chips_NNS ,_, and_CC both_DT genes_NNS were_VBD detected_VBN as_IN showing_VBG
          differential_NN expression_NN ._. Of_IN the_DT 19_CD unique_JJ genes_NNS with_IN
          decreased_VBD expression_NN in_IN MeCP_NNP 2_CD deficient_NN cells_NNS ,_, 12_CD are_VBP
          known_VBN to_TO be_VB expressed_VBN in_IN brain_NN (_( Table_NNP 2_LS )_) ._.
        
        
          Quantitative_NNP real-time_JJ RT-PCR_NNP analyses_NNS of_IN
          fibroblast_NN clones_NNS
          To_TO assess_VB the_DT reliability_NN of_IN the_DT array_NN hybridization_NN
          results_NNS ,_, transcript_NN levels_NNS of_IN 11_CD differentially_RB expressed_VBD
          genes_NNS (_( 8_CD with_IN increased_VBN and_CC 3_CD with_IN decreased_VBD expression_NN )_)
          were_VBD quantified_VBN using_VBG real-time_JJ quantitative_JJ RT-PCR_NNP
          analysis_NN with_IN Sybr_NNP Green_NNP ®_NN ._. The_DT same_JJ RNA_NNP samples_NNS used_VBN for_IN
          making_VBG array_NN hybridization_NN probes_NNS were_VBD used_VBN as_IN templates_NNS
          for_IN RT-PCR_NNP ._. The_DT Pearson_NNP correlation_NN coefficient_NN was_VBD 0_CD ._. 96_CD
          for_IN the_DT RT-PCR_NNP values_NNS from_IN triplicate_NN assays_NNS ._. The_DT fold_VB
          change_NN data_NNS from_IN the_DT GeneChips_NNP ®_NN and_CC RT-PCR_NNP analyses_NNS
          (_( Table_NNP 3_LS )_) were_VBD converted_VBN to_TO log_VB scale_NN for_IN analysis_NN and_CC
          comparison_NN ._. The_DT correlation_NN of_IN the_DT combined_VBN RT-PCR_NNP fold_VB
          change_NN data_NNS (_( based_VBN on_IN average_NN of_IN log_NN of_IN the_DT three_CD
          measurements_NNS from_IN each_DT wild-type_JJ and_CC each_DT mutant_JJ sample_NN )_)
          with_IN the_DT GeneChip_NNP ®_NN log_NN fold_VB change_NN data_NNS was_VBD ._. 92_CD (_( 95_CD %_NN CI_NNP =_SYM
          0_CD ._. 86_CD ,_, 0_CD ._. 96_CD )_) (_( Fig_NNP ._. 3_LS )_) ._.
          To_TO assess_VB the_DT consistency_NN of_IN differential_NN gene_NN
          expression_NN among_IN a_DT larger_JJR number_NN of_IN independently_RB derived_VBN
          cell_NN clones_NNS from_IN the_DT same_JJ individual_NN ,_, we_PRP selected_VBD five_CD
          genes_NNS with_IN large_JJ fold_VB change_NN values_NNS that_WDT had_VBD been_VBN
          identified_VBN by_IN microarray_NN analysis_NN and_CC confirmed_VBN by_IN
          RT-PCR_NNP ._. Three_CD genes_NNS with_IN increased_VBN expression_NN in_IN mutant_JJ
          clones_NNS (_( MTAP_NNP 44_CD ,_, MMP_NNP 3_CD and_CC NTN_NNP 4_LS )_) and_CC two_CD with_IN decreased_VBD
          expression_NN (_( CRIP_NNP 1_CD and_CC COMP_NNP )_) were_VBD quantitatively_RB tested_VBN in_IN
          multiple_JJ clonal_NN cell_NN strains_NNS from_IN two_CD Rett_NNP females_NNS (_( with_IN
          MECP_NNP 2_CD mutations_NNS 1155_CD del_FW 32_CD and_CC R_NN 106_CD W_NNP )_) using_VBG RT-PCR_NNP ._.
          Expression_NNP levels_NNS varied_VBD significantly_RB from_IN clone_NN to_TO
          clone_NN and_CC between_IN cell_NN strains_NNS (_( Fig_NNP ._. 4_LS )_) ._. Fold_NNP change_NN
          values_NNS for_IN the_DT multiple_JJ clone_NN comparisons_NNS were_VBD mostly_RB
          inconsistent_JJ with_IN the_DT original_JJ GeneChip_NNP /_NN RT-PCR_NNP data_NNS ._.
          Furthermore_RB ,_, the_DT 95_CD %_NN confidence_NN interval_NN for_IN fold_VB change_NN
          included_VBD 1_CD ._. 0_CD (_( no_DT change_NN )_) in_IN six_CD of_IN the_DT ten_CD comparisons_NNS
          (_( Fig_NNP ._. 5_LS )_) ._. Expression_NNP of_IN CRIP_NNP 1_CD was_VBD significantly_RB different_JJ
          between_IN wild-type_JJ and_CC mutant_JJ clones_NNS for_IN both_DT Rett_NNP
          individuals_NNS tested_VBN (_( p_NN =_SYM 0_CD ._. 004_CD and_CC p_NN =_SYM 0_CD ._. 035_CD )_) ,_, however_RB ,_,
          the_DT direction_NN of_IN change_NN was_VBD different_JJ ._. Increased_VBN
          expression_NN of_IN only_RB one_CD gene_NN ,_, MTAP_NNP 44_CD ,_, encoding_VBG the_DT
          interferon-inducible_JJ microtubular_NN aggregate_JJ protein_NN 44_CD ,_,
          remained_VBD significant_JJ in_IN comparison_NN of_IN the_DT mutant_JJ and_CC
          wild-type_JJ clones_NNS for_IN both_DT individuals_NNS tested_VBN (_( p_NN =_SYM 0_CD ._. 027_CD
          and_CC p_NN =_SYM 0_CD ._. 01_CD )_) (_( Fig_NNP ._. 5_LS )_) ._.
        
        
          Oligonucleotide_NNP array_NN hybridization_NN data_NNS of_IN
          lymphoblasts_NNS
          The_DT global_JJ gene_NN expression_NN pattern_NN in_IN fibroblasts_NNS is_VBZ
          limited_VBN ,_, and_CC single_JJ cell_NN cloning_VBG may_MD amplify_VB stochastic_JJ
          events_NNS in_IN culture_NN that_WDT may_MD be_VB responsible_JJ for_IN the_DT wide_JJ
          range_NN of_IN transcript_NN levels_NNS in_IN fibroblast_NN clones_NNS ._. We_PRP ,_,
          therefore_RB ,_, extended_VBD the_DT microarray_NN analyses_NNS to_TO
          lymphoblastoid_NN cell_NN lines_NNS (_( LCLs_NNP )_) and_CC studied_VBN four_CD clonal_NN
          mutant_JJ MeCP_NNP 2_CD (_( T_NN 158_CD M_NNP ,_, 803_CD delG_NN ,_, R_NN 168_CD X_NNP and_CC 1159_CD del_FW 28_CD )_)
          expressing_VBG and_CC one_CD clonal_NN (_( 1159_CD del_FW 28_CD )_) and_CC four_CD completely_RB
          skewed_VBN (_( R_NN 106_CD W_NNP ,_, R_NN 255_CD X_NNP ,_, 803_CD delG_NN ,_, 803_CD delG_NN )_) wild-type_JJ MeCP_NNP 2_CD
          expressing_VBG LCLs_NNP ._. The_DT percent_NN "_'' present_JJ "_'' calls_VBZ ranged_VBN from_IN
          13_CD %_NN (_( chip_NN D_NNP )_) to_TO 50_CD %_NN (_( chip_NN A_DT )_) and_CC ,_, as_IN for_IN the_DT fibroblast_NN
          data_NN ,_, standard_JJ deviations_NNS for_IN the_DT percent_NN "_'' present_JJ "_'' calls_VBZ
          for_IN a_DT given_VBN chip_NN were_VBD 1_CD -_: 3_CD %_NN ,_, and_CC differences_NNS in_IN percent_NN
          "_'' present_JJ "_'' calls_VBZ between_IN wild_JJ type_NN samples_NNS compared_VBN to_TO
          mutant_JJ samples_NNS were_VBD not_RB significant_JJ ._. When_WRB the_DT expression_NN
          profile_NN of_IN each_DT mutant_JJ was_VBD compared_VBN to_TO that_DT of_IN each_DT
          wild-type_JJ LCL_NNP ,_, 16_CD genes_NNS were_VBD found_VBN to_TO be_VB differentially_RB
          expressed_VBN in_IN at_IN least_JJS 15_CD of_IN 20_CD comparisons_NNS (_( Table_NNP 4_LS )_) ._.
          Eleven_CD genes_NNS showed_VBD increased_VBN levels_NNS of_IN expression_NN ,_, and_CC 5_CD
          showed_VBD decreased_VBN expression_NN ._. Of_IN those_DT 16_CD genes_NNS ,_, 12_CD are_VBP
          annotated_JJ as_IN known_VBN genes_NNS and_CC 9_CD are_VBP expressed_VBN in_IN brain_NN ._.
          Quantitative_NNP RT-PCR_NNP was_VBD performed_VBN on_IN four_CD genes_NNS (_( three_CD
          with_IN increased_VBN and_CC one_CD with_IN decreased_VBD expression_NN )_) to_TO
          assess_VB the_DT accuracy_NN of_IN GeneChip_NNP results_NNS ._. In_IN a_DT plot_NN
          similar_JJ to_TO that_DT shown_VBN in_IN Figure_NN 3_CD ,_, the_DT correlation_NN of_IN the_DT
          combined_VBN RT-PCR_NNP fold_VB change_NN data_NNS with_IN the_DT GeneChip_NNP ®_NN log_NN
          fold_VB change_NN data_NNS was_VBD 0_CD ._. 91_CD (_( data_NNS not_RB shown_VBN )_) ._.
        
      
      
        Discussion_NNP
        Random_NNP X_NNP inactivation_NN patterns_NNS are_VBP characteristic_JJ for_IN
        Rett_NNP syndrome_NN that_WDT is_VBZ caused_VBN by_IN heterozygosity_NN for_IN
        mutations_NNS in_IN the_DT X-_NNP linked_VBD locus_JJ MECP_NNP 2_CD ._. Our_PRP$ study_NN design_NN was_VBD
        intended_VBN to_TO take_VB advantage_NN of_IN the_DT mosaic_JJ X_NNP chromosome_NN
        inactivation_NN in_IN cell_NN strains_NNS of_IN Rett_NNP syndrome_NN females_NNS ._. From_IN
        four_CD original_JJ fibroblast_NN samples_NNS ,_, we_PRP generated_VBD clonally_RB
        derived_VBN cell_NN strains_NNS that_WDT expressed_VBD only_RB the_DT mutant_JJ MeCP_NNP 2_CD
        or_CC only_RB the_DT wild-type_JJ MECP_NNP 2_CD allele_NN ,_, but_CC not_RB both_DT ._. We_PRP
        hypothesized_VBN that_IN the_DT effects_NNS of_IN MeCP_NNP 2_CD dysfunction_NN in_IN the_DT
        mutant_JJ clonal_NN cell_NN strain_NN would_MD be_VB more_RBR pronounced_JJ than_IN in_IN
        the_DT original_JJ cell_NN strain_NN with_IN mosaic_JJ X_NNP chromosome_NN
        inactivation_NN ._. Moreover_RB ,_, we_PRP were_VBD able_JJ to_TO establish_VB the_DT ideal_JJ
        matched_VBN control_NN for_IN each_DT clonal_NN mutant_JJ cell_NN strain_NN ,_, a_DT
        clonal_NN cell_NN strain_NN with_IN the_DT wild-type_JJ MECP_NNP 2_CD allele_NN on_IN the_DT
        active_JJ X_NNP chromosome_NN from_IN the_DT same_JJ individual_NN ._. Comparative_NNP
        transcription_NN profiling_VBG of_IN matched_VBN pairs_NNS of_IN fibroblast_NN
        clones_NNS should_MD eliminate_VB any_DT noise_NN contributed_VBN by_IN
        polymorphisms_NNS or_CC mutations_NNS of_IN autosomal_NN genes_NNS ._.
        Although_IN MeCP_NNP 2_CD expression_NN is_VBZ higher_JJR in_IN other_JJ tissues_NNS
        such_JJ as_IN brain_NN ,_, spleen_NN and_CC lung_NN [_NN 16_CD ]_NN ,_, the_DT value_NN gained_VBN by_IN
        the_DT matched_VBN pair_NN comparisons_NNS of_IN clonal_NN skin_NN fibroblast_NN
        strains_NNS cultured_JJ under_IN identical_JJ environmental_JJ conditions_NNS ,_,
        should_MD overcome_VB the_DT drawbacks_NNS of_IN evaluating_VBG a_DT tissue_NN with_IN a_DT
        lower_JJR level_NN of_IN expression_NN ._. Previously_RB reported_VBD microarray_NN
        studies_NNS of_IN female_JJ Rett_NNP and_CC unrelated_JJ control_NN brain_NN samples_NNS
        revealed_VBD expression_NN changes_NNS that_WDT were_VBD interpreted_VBN as_IN
        secondary_JJ to_TO the_DT disease_NN process_NN ,_, such_JJ as_IN increased_VBN
        expression_NN of_IN glial-specific_JJ genes_NNS and_CC decreased_VBD expression_NN
        of_IN neuronal_NN genes_NNS [_NN 25_CD ]_NN ._. Therefore_RB ,_, when_WRB searching_VBG for_IN
        the_DT primary_JJ targets_NNS of_IN MeCP_NNP 2_CD modulation_NN ,_, it_PRP might_MD be_VB
        advantageous_JJ to_TO study_VB a_DT tissue_NN that_WDT is_VBZ less_RBR obviously_RB
        involved_VBN in_IN the_DT pathologic_JJ processes_NNS of_IN the_DT disease_NN ._.
        To_TO identify_VB potential_JJ target_NN genes_NNS of_IN MeCP_NNP 2_CD regulation_NN ,_,
        we_PRP looked_VBD for_IN genes_NNS with_IN increased_VBN transcript_NN levels_NNS in_IN at_IN
        least_JJS three_CD out_IN of_IN four_CD mutant_JJ /_NN wild-type_JJ MECP_NNP 2_CD expressing_VBG
        fibroblast_NN comparisons_NNS ._. Similarly_RB ,_, genes_NNS with_IN decreased_VBD
        expression_NN in_IN at_IN least_JJS three_CD out_IN of_IN four_CD matched_VBN pair_NN
        comparisons_NNS were_VBD also_RB considered_VBN potential_JJ targets_NNS of_IN MeCP_NNP 2_CD
        regulation_NN ._. If_IN the_DT calls_NNS made_VBN did_VBD not_RB reflect_VB real_JJ
        increases_NNS or_CC decreases_NNS ,_, we_PRP would_MD expect_VB expression_NN level_NN
        increases_NNS and_CC decreases_NNS to_TO be_VB scattered_VBN randomly_RB throughout_IN
        the_DT 63_CD ,_, 175_CD transcripts_NNS interrogated_VBN ._. By_IN random_JJ chance_NN
        alone_RB ,_, we_PRP would_MD expect_VB to_TO see_VB fewer_JJR than_IN four_CD genes_NNS
        increased_VBN in_IN three_CD of_IN four_CD comparisons_NNS and_CC fewer_JJR than_IN one_CD
        (_( 0_CD ._. 03_CD genes_NNS )_) increased_VBN in_IN four_CD of_IN four_CD comparisons_NNS ._. The_DT
        number_NN of_IN differentially_RB regulated_VBN genes_NNS identified_VBN by_IN
        these_DT criteria_NNS ,_, 49_CD with_IN increased_VBN and_CC 21_CD with_IN decreased_VBD
        expression_NN ,_, is_VBZ significantly_RB higher_JJR than_IN expected_VBN by_IN random_JJ
        chance_NN ,_, but_CC it_PRP is_VBZ much_RB lower_JJR than_IN one_PRP would_MD expect_VB if_IN MeCP_NNP 2_CD
        had_VBD a_DT crucial_JJ role_NN as_IN transcriptional_NN repressor_NN of_IN all_DT
        genes_NNS with_IN methylated_JJ promoters_NNS ._.
        To_TO validate_NN the_DT microarray_NN expression_NN data_NNS with_IN an_DT
        independent_JJ method_NN ,_, we_PRP carried_VBD out_IN real-time_JJ quantitative_JJ
        RT-PCR_NNP analyses_NNS for_IN a_DT sub-set_JJ of_IN 11_CD genes_NNS on_IN all_DT 8_CD samples_NNS
        that_WDT were_VBD used_VBN on_IN the_DT GeneChips_NNP ®_NN ._. The_DT results_NNS were_VBD
        amazingly_RB consistent_JJ for_IN fold_VB change_NN and_CC direction_NN of_IN
        change_NN in_IN almost_RB all_DT instances_NNS ._. We_PRP ,_, therefore_RB ,_, chose_VBD to_TO use_VB
        quantitative_JJ RT-PCR_NNP alone_RB to_TO assess_VB whether_IN the_DT increased_VBN
        or_CC decreased_VBN expression_NN patterns_NNS observed_VBD in_IN the_DT initial_JJ
        four_CD matched_VBN pairs_NNS of_IN clones_NNS were_VBD consistent_JJ in_IN other_JJ
        clones_NNS and_CC ,_, therefore_RB ,_, might_MD be_VB biologically_RB meaningful_JJ ._.
        Much_JJ to_TO our_PRP$ surprise_NN ,_, expression_NN levels_NNS of_IN 5_CD genes_NNS in_IN 11_CD
        additional_JJ MeCP_NNP 2_CD -_: deficient_NN and_CC 11_CD additional_JJ MeCP_NNP 2_CD -_: positive_JJ
        clones_NNS from_IN two_CD Rett_NNP individuals_NNS ,_, one_CD with_IN a_DT missense_NN and_CC
        one_CD with_IN a_DT truncating_VBG mutation_NN ,_, showed_VBD tremendous_JJ
        variation_NN ._. In_IN the_DT multiple_JJ clone_NN comparisons_NNS ,_, the_DT fold_VB
        change_NN values_NNS trended_JJ away_RB from_IN the_DT significant_JJ fold_VB
        changes_NNS seen_VBN on_IN the_DT GeneChips_NNP ®_NN and_CC RT-PCR_NNP of_IN the_DT original_JJ
        matched_VBN pair_NN comparisons_NNS toward_IN 1_CD ._. 0_CD (_( no_DT change_NN )_) ._. CRIP_NNP 1_CD
        expression_NN generated_VBD significant_JJ p_NN values_NNS ,_, but_CC the_DT
        direction_NN of_IN change_NN differed_VBD in_IN the_DT two_CD individuals_NNS tested_VBN ._.
        In_IN the_DT truncating_VBG mutation_NN 1155_CD del_FW 32_CD ,_, expression_NN was_VBD
        decreased_VBN and_CC in_IN the_DT missense_NN mutation_NN R_NN 106_CD W_NNP ,_, it_PRP was_VBD
        increased_VBN ._. Although_IN individual_JJ background_NN genetic_JJ
        differences_NNS between_IN the_DT two_CD Rett_NNP females_NNS might_MD be_VB
        responsible_JJ for_IN these_DT results_NNS ,_, the_DT possibility_NN that_IN the_DT
        opposite_JJ type_NN changes_NNS are_VBP mutation-type_JJ specific_JJ needs_VBZ to_TO
        be_VB evaluated_VBN by_IN studies_NNS of_IN clones_NNS from_IN additional_JJ
        patients_NNS ._.
        Only_RB MTAP_NNP 44_CD ,_, encoding_VBG the_DT interferon-inducible_JJ
        microtubular_NN aggregate_JJ protein_NN 44_CD ,_, remained_VBD significant_JJ in_IN
        comparison_NN of_IN the_DT mutant_JJ and_CC wild-type_JJ clones_NNS ,_, with_IN average_JJ
        increases_NNS of_IN 3_CD ._. 12_CD and_CC 5_CD ._. 58_CD fold_VB ,_, for_IN the_DT two_CD individuals_NNS
        tested_VBN ._. The_DT product_NN of_IN this_DT gene_NN was_VBD first_RB identified_VBN by_IN a_DT
        monoclonal_NN antibody_NN against_IN microtubular_NN aggregates_NNS in_IN
        hepatocytes_NNS of_IN chimpanzees_NNS infected_VBN with_IN hepatitis_NNP C_NNP virus_NN
        [_NN 26_CD ]_NN ._. The_DT production_NN of_IN p_NN 44_CD mRNA_NN is_VBZ markedly_RB induced_VBN in_IN
        the_DT liver_NN of_IN chimpanzees_NNS infected_VBN with_IN hepatitis_NNP C_NNP or_CC
        hepatitis_NNP D_NNP virus_NN [_NN 27_CD ]_NN ._. Inducibility_NNP by_IN
        interferon-alpha_JJ /_NN beta_NN ,_, but_CC not_RB by_IN interferon-gamma_JJ ,_, is_VBZ
        mediated_JJ by_IN an_DT interferon-stimulated_JJ response_NN element_NN in_IN
        the_DT promoter_NN region_NN [_NN 27_CD ]_NN ._. The_DT gene_NN was_VBD independently_RB
        identified_VBN in_IN a_DT search_NN for_IN novel_NN interferon-inducible_JJ genes_NNS
        in_IN the_DT mouse_NN (_( Dron_NNP ,_, M_NNP ._. ,_, Meritet_NNP ,_, J_NNP ._. F_NN ._. and_CC Tovey_NNP ,_, M_NNP ._. G_NNP ._.
        unpublished_JJ ,_, GenBank_NNP #_# AJ_NNP 299405_CD )_) ._. Also_RB known_VBN as_IN IFI_NNP 44_CD (_( for_IN
        Interferon-inducible_NNP protein_NN 44_CD )_) ,_, the_DT human_JJ gene_NN is_VBZ located_VBN
        on_IN chromosome_NN 1_CD p_NN 31_CD ._. 1_LS ._. Although_IN predominantly_RB expressed_VBD in_IN
        uterus_NN and_CC other_JJ internal_JJ organs_NNS ,_, transcripts_NNS have_VBP been_VBN
        isolated_VBN from_IN brain_NN and_CC hypothalamus_JJ cDNA_NN libraries_NNS (_( see_VB
        dbEST_NN )_) ._. The_DT putative_JJ function_NN of_IN this_DT protein_NN in_IN the_DT brain_NN
        is_VBZ still_RB a_DT mystery_NN ._.
        A_DT different_JJ design_NN was_VBD used_VBN for_IN the_DT microarray_NN study_NN of_IN
        Rett_NNP syndrome_NN LCLs_NNP ._. We_PRP initiated_VBD the_DT LCL_NNP study_NN because_IN
        MeCP_NNP 2_CD protein_NN expression_NN was_VBD higher_JJR in_IN lymphoblasts_NNS than_IN in_IN
        fibroblasts_NNS ,_, and_CC LCLs_NNP have_VBP an_DT overlapping_VBG expression_NN
        pattern_NN that_WDT includes_VBZ genes_NNS not_RB expressed_VBD in_IN fibroblasts_NNS ._.
        Because_IN of_IN skewed_VBN X_NNP inactivation_NN in_IN the_DT available_JJ LCLs_NNP ,_,
        however_RB ,_, we_PRP were_VBD only_RB able_JJ to_TO obtain_VB one_CD matched_VBN pair_NN of_IN
        mutant_JJ versus_CC wild-type_JJ expressing_VBG clones_NNS (_( for_IN 1159_CD del_FW 28_CD )_) ._.
        For_IN the_DT 20_CD different_JJ comparisons_NNS ,_, we_PRP included_VBD three_CD
        mutant-allele_JJ expressing_VBG clones_NNS (_( T_NN 158_CD M_NNP ,_, 803_CD delG_NN ,_, R_NN 168_CD X_NNP )_) and_CC
        four_CD completely_RB skewed_VBN wild-type_JJ MeCP_NNP 2_CD expressing_VBG LCLs_NNP
        (_( R_NN 106_CD W_NNP ,_, R_NN 255_CD X_NNP ,_, 803_CD delG_NN ,_, 803_CD delG_NN )_) from_IN different_JJ donors_NNS ._.
        Nevertheless_RB ,_, only_RB 16_CD differentially_RB expressed_VBD genes_NNS were_VBD
        identified_VBN ,_, with_IN a_DT sub-set_JJ confirmed_VBN by_IN quantitative_JJ
        RT-PCR_NNP ._. None_NN of_IN these_DT genes_NNS were_VBD identical_JJ to_TO any_DT
        candidates_NNS found_VBD in_IN the_DT fibroblast_NN study_NN ._. Gene_NNP expression_NN
        patterns_NNS in_IN primary_JJ fibroblasts_NNS and_CC transformed_VBN
        lymphoblasts_NNS are_VBP different_JJ and_CC /_NN or_CC may_MD respond_VB differently_RB
        to_TO MeCP_NNP 2_CD deficiency_NN ._. Several_JJ of_IN the_DT candidate_NN targets_NNS
        identified_VBN in_IN lymphoblasts_NNS that_WDT are_VBP also_RB expressed_VBN in_IN brain_NN
        (_( Table_NNP 4_LS )_) may_MD warrant_VB further_JJ evaluation_NN ._.
        While_IN our_PRP$ initial_JJ matched_VBN fibroblast_NN clonal_NN comparisons_NNS
        identified_VBD numerous_JJ genes_NNS with_IN consistent_JJ results_NNS that_WDT
        could_MD be_VB targets_NNS of_IN MeCP_NNP 2_CD modulation_NN ,_, verification_NN of_IN a_DT
        small_JJ subset_NN of_IN these_DT data_NNS by_IN comparing_VBG additional_JJ clones_NNS
        not_RB used_VBN on_IN the_DT GeneChip_NNP ®_NN analysis_NN revealed_VBD amazing_JJ
        inconsistency_NN ._. The_DT variability_NN of_IN gene_NN expression_NN across_IN
        clonal_NN cell_NN strains_NNS with_IN the_DT same_JJ genotype_NN and_CC the_DT same_JJ X_NNP
        chromosome_NN active_JJ was_VBD similar_JJ among_IN clones_NNS expressing_VBG the_DT
        mutant_JJ or_CC the_DT wild-type_JJ MECP_NNP 2_CD allele_NN ._. Therefore_RB ,_, it_PRP is_VBZ not_RB
        likely_JJ to_TO result_VB from_IN MeCP_NNP 2_CD dysfunction_NN and_CC we_PRP can_MD exclude_VB
        the_DT possibility_NN that_IN MECP_NNP 2_CD mutations_NNS lead_VBP to_TO transcript_NN
        instability_NN ._. More_RBR likely_JJ ,_, fibroblasts_NNS in_IN culture_NN undergo_VBP
        random_JJ modification_NN of_IN gene_NN expression_NN ,_, by_IN somatic_JJ
        mutations_NNS or_CC epigenetic_JJ regulation_NN ,_, and_CC such_JJ rare_JJ events_NNS
        may_MD be_VB amplified_VBN in_IN single-cell_JJ derived_VBN clones_NNS ._. In_IN uncloned_JJ
        fibroblast_NN populations_NNS ,_, RNA_NNP samples_NNS from_IN replicate_VB cultures_NNS
        revealed_VBD consistent_JJ results_NNS in_IN comparative_JJ large-scale_JJ gene_NN
        expression_NN studies_NNS [_NN 28_CD ]_NN ._. Cell_NNP lines_NNS ,_, i_NNP ._. e_SYM ._. transformed_VBN ,_,
        immortalized_JJ or_CC tumor-derived_JJ cell_NN lines_NNS ,_, are_VBP well_RB known_VBN to_TO
        be_VB heteroploid_NN i_NNP ._. e_SYM ._. chromosomally_RB unstable_JJ ,_, and_CC any_DT
        single-cell_JJ derived_VBN clones_NNS of_IN such_JJ lines_NNS are_VBP genetically_RB
        heterogeneous_JJ ._. Therefore_RB ,_, some_DT differences_NNS in_IN transcript_NN
        levels_NNS among_IN such_JJ clones_NNS would_MD not_RB be_VB surprising_JJ ._. There_EX are_VBP
        almost_RB no_DT reports_NNS in_IN the_DT literature_NN ,_, however_RB ,_, on_IN
        comparative_JJ gene_NN expression_NN studies_NNS in_IN clones_NNS of_IN primary_JJ
        fibroblasts_NNS ._. One_CD of_IN the_DT reasons_NNS may_MD be_VB that_IN it_PRP is_VBZ difficult_JJ
        to_TO generate_VB such_JJ clones_NNS ._. In_IN 1981_CD ,_, Griffin_NNP et_CC al_NN [_NN 29_CD ]_NN
        reported_VBD variation_NN in_IN the_DT activity_NN of_IN steroid_NN 5_CD alpha_NN
        reductase_NN ,_, the_DT enzyme_NN that_WDT converts_VBZ testosterone_NN to_TO
        dihydrotestosterone_NN ,_, in_IN cloned_VBN human_JJ skin_NN fibroblasts_NNS ._.
        Activity_NN of_IN this_DT enzyme_NN is_VBZ low_JJ in_IN non-genital_JJ skin_NN but_CC high_JJ
        in_IN genital_JJ skin_NN cells_NNS that_WDT grow_VBP in_IN response_NN to_TO androgen_NN ._.
        Foreskin-derived_NNP fibroblast_NN clones_NNS varied_VBD greatly_RB (_( up_IN to_TO
        200_CD fold_VB )_) in_IN enzyme_NN activity_NN ._. The_DT range_NN of_IN activity_NN for_IN
        other_JJ microsomal_NN enzymes_NNS was_VBD much_RB lower_JJR in_IN the_DT same_JJ
        fibroblast_NN clones_NNS ._. These_DT authors_NNS did_VBD not_RB study_VB mRNA_NN levels_NNS
        but_CC reductase_NN activity_NN ,_, therefore_RB ,_, variation_NN at_IN the_DT level_NN
        of_IN protein_NN stability_NN could_MD also_RB play_VB a_DT role_NN ._.
        Our_PRP$ data_NNS could_MD be_VB interpreted_VBN to_TO suggest_VB that_IN microarray_NN
        experiments_NNS should_MD be_VB performed_VBN on_IN greater_JJR numbers_NNS of_IN
        samples_NNS and_CC /_NN or_CC samples_NNS from_IN mutant_JJ and_CC wild-type_JJ brain_NN to_TO
        generate_VB meaningful_JJ data_NNS ._. It_PRP is_VBZ instructive_JJ ,_, however_RB ,_, that_IN
        Tudor_NNP and_CC colleagues_NNS compared_VBD global_JJ gene_NN expression_NN in_IN a_DT
        large_JJ number_NN of_IN wild-type_JJ and_CC 
        Mecp_NNP 2_CD -_: null_NN male_JJ mice_NNS and_CC failed_VBD to_TO
        identify_VB striking_JJ changes_NNS in_IN gene_NN expression_NN in_IN the_DT brain_NN [_NN
        30_CD ]_NN ._.
      
      
        Conclusions_NNP
        Both_DT fibroblast_NN and_CC lymphoblast_NN data_NNS together_RB agree_VBP in_IN
        the_DT most_RBS important_JJ positive_JJ result_NN of_IN our_PRP$ studies_NNS :_: MeCP_NNP 2_CD
        deficiency_NN does_VBZ not_RB result_VB in_IN global_JJ deregulation_NN of_IN gene_NN
        expression_NN ._. This_DT result_NN is_VBZ novel_NN and_CC unexpected_JJ in_IN light_NN of_IN
        the_DT purported_JJ function_NN of_IN MeCP_NNP 2_CD as_IN a_DT global_JJ transcriptional_NN
        regulator_NN that_WDT was_VBD based_VBN on_IN in_IN vitro_NN biochemical_JJ studies_NNS ._.
        There_EX are_VBP several_JJ possibilities_NNS that_WDT might_MD explain_VB our_PRP$
        findings_NNS ._. First_LS ,_, redundancy_NN in_IN methyl-_NN CpG_NNP binding_JJ proteins_NNS
        that_WDT recruit_NN transcriptional_NN silencing_VBG complexes_NNS may_MD mask_NN
        the_DT effects_NNS of_IN MeCP_NNP 2_CD deficiency_NN ;_: for_IN example_NN ,_, MBD_NNP 1_CD ,_, MBD_NNP 2_CD or_CC
        Kaiso_NNP ,_, may_MD complement_VB the_DT defect_NN in_IN the_DT cell_NN types_NNS we_PRP
        studied_VBD ._. Second_JJ ,_, if_IN the_DT inter-clonal_JJ variation_NN we_PRP detected_VBD
        by_IN the_DT quantitative_JJ RT-PCR_NNP study_NN of_IN 5_CD genes_NNS in_IN 22_CD clones_NNS
        from_IN two_CD different_JJ Rett_NNP individuals_NNS were_VBD representative_NN of_IN
        a_DT general_JJ feature_NN of_IN diploid_NN fibroblast_NN clones_NNS ,_, it_PRP could_MD
        have_VB masked_VBN any_DT consistent_JJ biologically_RB meaningful_JJ
        expression_NN changes_NNS ._. If_IN our_PRP$ limited_JJ findings_NNS were_VBD confirmed_VBN
        by_IN larger-scale_JJ studies_NNS ,_, we_PRP would_MD need_VB to_TO conclude_VB that_DT
        clonal_NN fibroblast_NN strains_NNS are_VBP not_RB a_DT suitable_JJ resource_NN for_IN
        genome-wide_JJ expression_NN profiling_VBG studies_NNS ._. Third_NNP ,_,
        deregulation_NN of_IN very_RB few_JJ genes_NNS expressed_VBD only_RB in_IN parts_NNS of_IN
        the_DT brain_NN ,_, or_CC only_RB under_IN certain_JJ conditions_NNS ,_, may_MD be_VB
        responsible_JJ for_IN the_DT neuronal_NN abnormalities_NNS in_IN Rett_NNP brains_NNS ,_,
        and_CC this_DT would_MD not_RB be_VB detected_VBN by_IN microarray_NN studies_NNS ._.
        Fourth_JJ ,_, MeCP_NNP 2_CD action_NN on_IN chromatin_NN ,_, as_IN suggested_VBN by_IN observed_VBD
        changes_NNS in_IN histone_NN acetylation_NN [_NN 31_CD 32_CD ]_NN ,_, may_MD not_RB involve_VB
        protein_NN coding_VBG genes_NNS that_WDT are_VBP represented_VBN on_IN microarrays_NNS ,_,
        but_CC instead_RB ,_, may_MD affect_VB centromeric_JJ heterochromatin_NN or_CC the_DT
        expression_NN of_IN small_JJ non-coding_JJ RNAs_NNP that_WDT are_VBP abundant_JJ in_IN
        normal_JJ brain_NN [_NN 33_CD ]_NN ._. The_DT results_NNS presented_VBN in_IN this_DT paper_NN
        contradict_VB the_DT established_VBN model_NN of_IN MeCP_NNP 2_CD function_NN and_CC
        necessitate_NN a_DT rethinking_VBG of_IN strategies_NNS to_TO unravel_VB the_DT
        pathologic_JJ process_NN that_WDT leads_VBZ to_TO neuronal_NN dysfunction_NN in_IN
        Rett_NNP syndrome_NN ._.
      
      
        List_NN of_IN abbreviations_NNS
        cDNA_NN complementary_JJ deoxyribonucleic_JJ acid_NN
        DNA_NNP deoxyribonucleic_JJ acid_NN
        EST_NNP expressed_VBD sequence_NN tag_NN
        mRNA_NN messenger_NN ribonucleic_JJ acid_NN
        PCR_NNP polymerase_NN chain_NN reaction_NN
        μl_NN microliter_NN
        μm_NN micrometer_NN
        ml_NN milliliter_NN
        mm_NN millimeter_NN
        mM_NN millimolar_NN
        ng_NN nanogram_NN
        nM_NN nanomolar_NN
        RNA_NNP ribonucleic_JJ acid_NN
        RT_NNP reverse_VB transcription_NN
        RT-PCR_NNP reverse_VB transcription_NN -_: polymerase_NN chain_NN
        reaction_NN
        U_NNP unit_NN
        IVT_NNP in-vitro_JJ transcription_NN
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        JT_NNP carried_VBD out_RP the_DT cell_NN culture_NN ,_, single_JJ cell_NN cloning_VBG ,_,
        nucleic_JJ acid_NN extraction_NN ,_, X_NNP chromosome_NN inactivation_NN studies_NNS ,_,
        mutation_NN analysis_NN ,_, sample_NN preparation_NN for_IN array_NN
        hybridization_NN ,_, microarray_NN analysis_NN ,_, real-time_JJ quantitative_JJ
        PCR_NNP and_CC some_DT of_IN the_DT statistical_JJ analysis_NN ,_, and_CC drafted_VBD the_DT
        manuscript_NN ._. PA_NNP performed_VBD the_DT immunoblot_NN analysis_NN ._. LL_NNP
        performed_VBD the_DT most_JJS of_IN the_DT statistical_JJ analysis_NN ._. UF_NNP
        conceived_VBD the_DT study_NN design_NN ,_, supervised_JJ and_CC coordinated_VBN its_PRP$
        progress_NN and_CC prepared_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
